BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABS-1230 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABS-1230\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07156201-8907@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ABS-1230: Phase 1 readout est. (NCT07156201)
DESCRIPTION:ABS-1230\, phase 1\, Epilepsy.\nStudy: A Study to Investigate t
 he Safety\, Tolerability\, and Pharmacokinetics of ABS-1230 Given Orally C
 ompared With Placebo in Healthy Participants Aged 18 to 55 Years\nEstimate
 d primary completion: December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abs-1230#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07156201
URL:https://assetmemo.bio/drug/abs-1230#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600736-8907@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:ABS-1230: Phase 2 readout est. (NCT07600736)
DESCRIPTION:ABS-1230\, phase 2\, Epilepsy.\nStudy: A Study to Investigate t
 he Safety\, Tolerability\, Pharmacokinetics\, and Clinical Activity of ABS
 -1230 in Pediatric and Young Adult Participants With KCNT1-related Epileps
 y\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/abs-1230#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07600736
URL:https://assetmemo.bio/drug/abs-1230#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
